UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 26

Sortiert nach

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC

Journal of thoracic oncology, 2019-02, Vol.14 (2), p.193-202

2019

Volltextzugriff (PDF)

Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2018-01, Vol.13 (1), p.106-111

2018

Volltextzugriff (PDF)

Characteristics and Outcome of ROS1-Positive Non–Small Cell Lung Cancer Patients in Routine Clinical Practice

Journal of thoracic oncology, 2018-09, Vol.13 (9), p.1373-1382

2018

Volltextzugriff (PDF)

Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication

Journal of thoracic oncology, 2018-08, Vol.13 (8), p.1106-1112

2018

Volltextzugriff (PDF)

Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status

Journal of thoracic oncology, 2020-11, Vol.15 (11), p.1758-1766

2020

Volltextzugriff (PDF)

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment

Journal of thoracic oncology, 2016-01, Vol.11 (1), p.e1-e4

2016

Volltextzugriff (PDF)

DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC

Journal of thoracic oncology, 2019-09, Vol.14 (9), p.1640-1650

2019

Volltextzugriff (PDF)

Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial

Journal of thoracic oncology, 2022-07, Vol.17 (7), p.900-908

2022

Volltextzugriff (PDF)

Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor

Journal of thoracic oncology, 2019-09, Vol.14 (9), p.1608-1618

2019

Volltextzugriff (PDF)

Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: “Stop or Go” Decision

Journal of thoracic oncology, 2016-12, Vol.11 (12), p.2051-2052

2016

Volltextzugriff (PDF)

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.e45-e47

2016

Volltextzugriff (PDF)

A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21)

Journal of thoracic oncology, 2023-02, Vol.18 (2), p.223-231

2023

Volltextzugriff (PDF)

Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2023-09, Vol.18 (9), p.1199-1208

2023

Volltextzugriff (PDF)

Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2018-03, Vol.13 (3), p.e34-e36

2018

Volltextzugriff (PDF)

KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma

Journal of thoracic oncology, 2018-03, Vol.13 (3), p.e29-e31

2018

Volltextzugriff (PDF)

Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC

Journal of thoracic oncology, 2023-07, Vol.18 (7), p.896-906

2023

Volltextzugriff (PDF)

Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2017-12, Vol.12 (12), p.1806-1813

2017

Volltextzugriff (PDF)

A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors

Journal of thoracic oncology, 2015-12, Vol.10 (12), p.1800-1806

2015

Volltextzugriff (PDF)

P3.02c-035 Comparison of RECIST to Immune-Related Response Criteria (irRC) in Patients with NSCLC Treated with Immune-Check Point Inhibitor

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1294-S1295

2017

Volltextzugriff (PDF)

P3.02c-035 Comparison of RECIST to Immune-Related Response Criteria (irRC) in Patients with NSCLC Treated with Immune-Check Point Inhibitor: Topic: IT

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1294-S1295

2017

Volltextzugriff (PDF)

Erlotinib Monotherapy for Stage IIIB/IV Non-small Cell Lung Cancer: A Multicenter Trial by the Korean Cancer Study Group

Journal of thoracic oncology, 2009-09, Vol.4 (9), p.1136-1143

2009

Volltextzugriff (PDF)

P3.02b-078 Non-Small Cell Lung Cancer with De Novo EGFR T790M Mutation: Clinical Features of 22 Cases: Topic: EGFR Clinical

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1237-S1238

2017

Volltextzugriff (PDF)

P3.02b-078 Non-Small Cell Lung Cancer with De Novo EGFR T790M Mutation: Clinical Features of 22 Cases

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1237-S1238

2017

Volltextzugriff (PDF)

Efficacy and safety of dovitinib in pretreated advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase II study

Journal of thoracic oncology, 2016-02, Vol.11 (2), p.S16-S16

2016

Volltextzugriff (PDF)

P3-060: Survival benefit of EGFR gene mutations and gene amplification in advanced NSCLC patients treated with erlotinib by the Korean Cancer Study Group (KCSG)

Journal of thoracic oncology, 2007-08, Vol.2 (8), p.S703-S703

2007

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Thoracic Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(26)

Sprache

Englisch
(26)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(19)
Oncology
(19)
Respiratory System
(19)
Science & Technology
(19)
Humans
(14)
Lung Neoplasms - Drug Therapy
(9)
Female
(8)
Middle Aged
(8)
Non–small Cell Lung Cancer
(7)
Aged
(6)
Lung Neoplasms - Genetics
(6)
Lung Neoplasms - Pathology
(6)
Male
(6)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(5)
Erbb Receptors - Genetics
(5)
Adult
(4)
Mutation
(4)
Protein Kinase Inhibitors - Therapeutic Use
(4)
Retrospective Studies
(4)
Adenocarcinoma - Drug Therapy
(3)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Elektronische Zeitschriftenbibliothek - Freely accessible e-journals
(26)
Journals@OVID
(26)
MEDLINE
(14)
IngentaConnect
(13)

Menü

Weitere Dienste

Einstellungen

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC

Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung Cancer

Characteristics and Outcome of ROS1-Positive Non–Small Cell Lung Cancer Patients in Routine Clinical Practice

Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication

Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment

DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC

Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial

Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor

Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: “Stop or Go” Decision

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer

A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21)

Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non–Small Cell Lung Cancer

Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non–Small Cell Lung Cancer

KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma

Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC

Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non–Small Cell Lung Cancer

A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors

P3.02c-035 Comparison of RECIST to Immune-Related Response Criteria (irRC) in Patients with NSCLC Treated with Immune-Check Point Inhibitor

P3.02c-035 Comparison of RECIST to Immune-Related Response Criteria (irRC) in Patients with NSCLC Treated with Immune-Check Point Inhibitor: Topic: IT

Erlotinib Monotherapy for Stage IIIB/IV Non-small Cell Lung Cancer: A Multicenter Trial by the Korean Cancer Study Group

P3.02b-078 Non-Small Cell Lung Cancer with De Novo EGFR T790M Mutation: Clinical Features of 22 Cases: Topic: EGFR Clinical

P3.02b-078 Non-Small Cell Lung Cancer with De Novo EGFR T790M Mutation: Clinical Features of 22 Cases

Efficacy and safety of dovitinib in pretreated advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase II study

P3-060: Survival benefit of EGFR gene mutations and gene amplification in advanced NSCLC patients treated with erlotinib by the Korean Cancer Study Group (KCSG)

Aktive Filter

Suchergebnisse filtern